SiBone (NASDAQ:SIBN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of SiBone (NASDAQ:SIBN) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $23.00.

A number of brokerages have commented on SIBN. TD Cowen decreased their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Truist Financial reaffirmed a “buy” rating and issued a $18.00 price objective (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. Finally, Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th.

Insider Buying and Selling at SiBone

In other news, CEO Laura Francis sold 14,957 shares of SiBone stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $14.71, for a total transaction of $220,017.47. Following the transaction, the chief executive officer owned 503,444 shares in the company, valued at $7,405,661.24. The trade was a 2.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Anshul Maheshwari sold 3,318 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $12.87, for a total value of $42,702.66. Following the completion of the sale, the chief financial officer owned 263,148 shares in the company, valued at approximately $3,386,714.76. This trade represents a 1.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,327 shares of company stock worth $520,834 over the last three months. Company insiders own 4.00% of the company’s stock.

Institutional Trading of SiBone

A number of institutional investors have recently modified their holdings of SIBN. First Light Asset Management LLC lifted its position in SiBone by 162.4% during the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock worth $99,249,000 after buying an additional 3,115,001 shares in the last quarter. Granahan Investment Management LLC lifted its position in SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after buying an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its position in SiBone by 113.3% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after buying an additional 598,300 shares in the last quarter. Cadian Capital Management LP lifted its position in SiBone by 96.8% during the 4th quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock worth $23,094,000 after buying an additional 576,100 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in SiBone by 22.5% during the 3rd quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after buying an additional 521,683 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

SiBone Stock Performance

Shares of NASDAQ SIBN opened at $16.34 on Friday. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20. The business’s 50 day moving average is $14.31 and its two-hundred day moving average is $15.60. The company has a market cap of $724.68 million, a P/E ratio of -41.90 and a beta of 0.70. SiBone has a 12 month low of $11.48 and a 12 month high of $21.89.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The company had revenue of $52.59 million for the quarter, compared to the consensus estimate of $51.16 million. On average, equities analysts expect that SiBone will post -0.44 EPS for the current year.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.